Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Medical Officer | August 04, 2026 | August 06, 2026 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date August 04, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 54,645 |
Reported balance
After 2026-08-04 transaction · row 1
1 source rowRow 1 · 2026-08-04 · Sale · Disposed 30,000 · Balance 54,645 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $30.25 to $30.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $30.25 to $30.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Viridian Therapeutics, Inc.\DE
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2036-07-01 | Direct | 32,341 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 32,341 · Balance 32,341 F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2026 Filed Aug 6, 2026 20:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 30,000 | $30.48 | $914,400.00 |
DisclosureSEC source: 0001439222-26-000120 · wk-form4_1786047196.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,645 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $30.25 to $30.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:15 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 32,341 | $0.00 Strike: $18.48 | $0.00 |
DisclosureSEC source: 0001193125-26-294552 · ownership.xml · derivative · entry 1 Gheuens Sarah · CIK 0001881190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,341 Underlying: Common Stock · 32,341 shares Expires 2036-07-01 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 8,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000110 · wk-form4_1783022592.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 8,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 4,007 | $37.56 | $150,502.92 |
DisclosureSEC source: 0001439222-26-000110 · wk-form4_1783022592.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,645 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated July 1, 2023. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 8,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000110 · wk-form4_1783022592.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000085 · wk-form4_1782249348.xml · derivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000085 · wk-form4_1782249348.xml · derivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000065 · wk-form4_1775506198.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,500 Underlying: Common stock · 8,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,940 | $34.71 | $102,047.40 |
DisclosureSEC source: 0001439222-26-000065 · wk-form4_1775506198.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,277 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000065 · wk-form4_1775506198.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 311 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000040 · wk-form4_1772572555.xml · derivative · entry 12 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,000 Underlying: Common stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F9 · derivative.exercise_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. F9 · derivative.expiration_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 5,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000040 · wk-form4_1772572555.xml · derivative · entry 11 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,667 Underlying: Common stock · 5,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F8 · derivative.exercise_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. F8 · derivative.expiration_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000040 · wk-form4_1772572555.xml · derivative · entry 10 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F7 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F7 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,187 | $28.96 | $34,375.52 |
DisclosureSEC source: 0001439222-26-000040 · wk-form4_1772572555.xml · nonDerivative · entry 6 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,406 F3 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000040 · wk-form4_1772572555.xml · nonDerivative · entry 5 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,681 | $28.96 | $48,681.76 |
DisclosureSEC source: 0001439222-26-000040 · wk-form4_1772572555.xml · nonDerivative · entry 4 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,593 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000040 · wk-form4_1772572555.xml · nonDerivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,187 | $28.96 | $34,375.52 |
DisclosureSEC source: 0001439222-26-000040 · wk-form4_1772572555.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,608 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000040 · wk-form4_1772572555.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 52,000 | $0.00 Strike: $30.23 | $0.00 |
DisclosureSEC source: 0001439222-26-000040 · wk-form4_1772572555.xml · derivative · entry 9 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,000 Underlying: Common stock · 52,000 shares Expires 2036-03-01 F6 · derivative.exercise_date: This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000040 · wk-form4_1772572555.xml · derivative · entry 8 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,000 Underlying: Common stock · 22,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments. F5 · derivative.expiration_date: The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000040 · wk-form4_1772572555.xml · derivative · entry 7 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,000 Underlying: Common stock · 14,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments. F5 · derivative.expiration_date: The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| December 30, 2025 Filed Jan 3, 2026 01:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000006 · wk-form4_1767402940.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| December 30, 2025 Filed Jan 3, 2026 01:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,932 | $27.09 | $79,427.88 |
DisclosureSEC source: 0001439222-26-000006 · wk-form4_1767402940.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,795 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023. Read SEC document |
| December 30, 2025 Filed Jan 3, 2026 01:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000006 · wk-form4_1767402940.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 2,454 | $0.00 Strike: $25.01 | $0.00 |
DisclosureSEC source: 0001439222-25-000118 · wk-form4_1763068136.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,130 Underlying: Common stock · 2,454 shares Expires 2033-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,454 | $43.78 | $107,436.12 |
DisclosureSEC source: 0001439222-25-000118 · wk-form4_1763068136.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,727 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $43.77 to $43.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,454 | $25.01 | $61,374.54 |
DisclosureSEC source: 0001439222-25-000118 · wk-form4_1763068136.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 200 | $0.00 Strike: $25.01 | $0.00 |
DisclosureSEC source: 0001881190-25-000004 · wk-form4_1762204249.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,584 Underlying: Common stock · 200 shares Expires 2033-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 200 | $43.81 | $8,762.00 |
DisclosureSEC source: 0001881190-25-000004 · wk-form4_1762204249.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,727 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 200 | $25.01 | $5,002.00 |
DisclosureSEC source: 0001881190-25-000004 · wk-form4_1762204249.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 3,302 | $0.00 Strike: $25.01 | $0.00 |
DisclosureSEC source: 0001439222-25-000111 · wk-form4_1761768146.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,784 Underlying: Common stock · 3,302 shares Expires 2033-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 3,302 | $43.92 | $145,023.84 |
DisclosureSEC source: 0001439222-25-000111 · wk-form4_1761768146.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,727 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $43.77 to $44.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,302 | $25.01 | $82,583.02 |
DisclosureSEC source: 0001439222-25-000111 · wk-form4_1761768146.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 456 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:59 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 11,914 | $0.00 Strike: $25.01 | $0.00 |
DisclosureSEC source: 0001439222-25-000082 · wk-form4_1752267546.xml · derivative · entry 4 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,086 Underlying: Common stock · 11,914 shares Expires 2033-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:59 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 847 | $38.76 | $32,829.72 |
DisclosureSEC source: 0001439222-25-000082 · wk-form4_1752267546.xml · nonDerivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,271 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $38.55 to $38.87. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:59 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 11,067 | $37.93 | $419,771.31 |
DisclosureSEC source: 0001439222-25-000082 · wk-form4_1752267546.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,118 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $37.52 to $38.49. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:59 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 11,914 | $25.01 | $297,969.14 |
DisclosureSEC source: 0001439222-25-000082 · wk-form4_1752267546.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:43 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000950170-25-093099 · ownership.xml · derivative · entry 1 Gheuens Sarah · CIK 0001881190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2035-07-01 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 8,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000073 · wk-form4_1751572884.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,375 Underlying: Common stock · 8,374 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 4,091 | $34.17 | $139,789.47 |
DisclosureSEC source: 0001439222-25-000073 · wk-form4_1751572884.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,271 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated July 1, 2023. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 8,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000073 · wk-form4_1751572884.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000069 · wk-form4_1750973125.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 Underlying: Common stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,909 | $33.54 | $97,567.86 |
DisclosureSEC source: 0001439222-25-000069 · wk-form4_1750973125.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,988 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000069 · wk-form4_1750973125.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,681 | $35.54 | $59,742.74 |
DisclosureSEC source: 0001439222-25-000013 · wk-form4_1741122508.xml · nonDerivative · entry 6 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,897 F4 · kind: hares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,187 | $35.54 | $42,185.98 |
DisclosureSEC source: 0001439222-25-000013 · wk-form4_1741122508.xml · nonDerivative · entry 4 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,911 F3 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,137 | $35.54 | $40,408.98 |
DisclosureSEC source: 0001439222-25-000013 · wk-form4_1741122508.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,098 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 5,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000013 · wk-form4_1741122508.xml · derivative · entry 11 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,333 Underlying: Common stock · 5,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F10 · derivative.exercise_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. F10 · derivative.expiration_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000013 · wk-form4_1741122508.xml · derivative · entry 10 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,000 Underlying: Common stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F9 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F9 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.